Id |
Subject |
Object |
Predicate |
Lexical cue |
T29 |
0-151 |
Sentence |
denotes |
The virtual screening process permitted the identification of a small set of drugs as prospective nonselective BK ligands, as described elsewhere [24]. |
T30 |
152-320 |
Sentence |
denotes |
Specifically, the DrugBank database, containing a total of 1703 molecules, was screened for compounds that fulfilled a common pharmacophore for the B1 and B2 receptors. |
T31 |
321-458 |
Sentence |
denotes |
The study identified eight drugs including raloxifene, sildenafil, cefepime, cefpirome, imatinib, ponatinib, abemaciclib and entrectinib. |
T32 |
459-641 |
Sentence |
denotes |
Subsequently, the eight compounds were purchased and tested for their capacity to displace a reference ligand in any of the two bradykinin receptors B1 and B2, respectively at 20 µM. |
T33 |
642-820 |
Sentence |
denotes |
Three of the compounds including raloxifene, sildenafil and cefepime displaced the reference ligand from B2, which represents a 40% success rate as found in similar studies [29]. |
T34 |
821-913 |
Sentence |
denotes |
However, none of the compounds exhibited affinity for the B1 receptor at this concentration. |
T35 |
914-1019 |
Sentence |
denotes |
This might be due to the steric hindrance that was not properly included in the virtual screening search. |
T36 |
1020-1156 |
Sentence |
denotes |
Raloxifene, the most potent antagonist identified was further investigated in a functional study in vitro, exhibiting an IC50 of ~16 µM. |
T37 |
1157-1250 |
Sentence |
denotes |
Moreover, the compound showed a weak partial agonist profile with a maximal activity of ~20%. |
T38 |
1251-1416 |
Sentence |
denotes |
Ralixofene is a selective estrogen receptor modulator, exerting estrogen agonist action in some target tissues while acting as an estrogen antagonist in others [30]. |
T39 |
1417-1556 |
Sentence |
denotes |
The compound was approved a few years ago for the treatment of osteoporosis in postmenopausal women, as well as for cancer chemoprotection. |
T40 |
1557-1743 |
Sentence |
denotes |
The discovery of a new pharmacodynamic profile of relixofene as a BK partial agonist opens an opportunity for its repurposing as a therapeutic agent for the treatment of severe Covid-19. |